Similarly, the discovery of other MSAs, such as anti-melanoma differentiation-associated protein-5 (anti-MDA5) and anti-TIF1γ, has led to the identification of new subtypes of dermatomyositis with distinct clinical and prognostic features [7, 8]. Here, IFIH1 is linked to dermatomyositis.